CA3104470A1 - Anti-factor xii/xiia antibodies and uses thereof - Google Patents

Anti-factor xii/xiia antibodies and uses thereof Download PDF

Info

Publication number
CA3104470A1
CA3104470A1 CA3104470A CA3104470A CA3104470A1 CA 3104470 A1 CA3104470 A1 CA 3104470A1 CA 3104470 A CA3104470 A CA 3104470A CA 3104470 A CA3104470 A CA 3104470A CA 3104470 A1 CA3104470 A1 CA 3104470A1
Authority
CA
Canada
Prior art keywords
antibody
amino acid
antigen
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3104470A
Other languages
English (en)
French (fr)
Inventor
Dan CHALOTHORN
Lori C. Morton
Lyndon MITNAUL
Kehdih LAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3104470A1 publication Critical patent/CA3104470A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F3/00—Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements
    • H03F3/45—Differential amplifiers
    • H03F3/45071—Differential amplifiers with semiconductor devices only
    • H03F3/45076—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier
    • H03F3/45475—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier using IC blocks as the active amplifying circuit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2203/00—Indexing scheme relating to amplifiers with only discharge tubes or only semiconductor devices as amplifying elements covered by H03F3/00
    • H03F2203/45—Indexing scheme relating to differential amplifiers
    • H03F2203/45444—Indexing scheme relating to differential amplifiers the CMCL comprising a sample and hold circuit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Power Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Amplifiers (AREA)
CA3104470A 2018-06-19 2019-06-19 Anti-factor xii/xiia antibodies and uses thereof Pending CA3104470A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687144P 2018-06-19 2018-06-19
US62/687,144 2018-06-19
PCT/US2019/037865 WO2019246176A1 (en) 2018-06-19 2019-06-19 Anti-factor xii/xiia antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3104470A1 true CA3104470A1 (en) 2019-12-26

Family

ID=67263076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3104470A Pending CA3104470A1 (en) 2018-06-19 2019-06-19 Anti-factor xii/xiia antibodies and uses thereof

Country Status (12)

Country Link
US (1) US12068729B2 (https=)
EP (1) EP3810270A1 (https=)
JP (2) JP7634993B2 (https=)
KR (1) KR20210022650A (https=)
CN (1) CN112437682B (https=)
AU (1) AU2019288299B2 (https=)
CA (1) CA3104470A1 (https=)
EA (1) EA202190056A1 (https=)
IL (1) IL279529A (https=)
MA (1) MA52966A (https=)
MX (1) MX2020013894A (https=)
WO (1) WO2019246176A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4175669A4 (en) * 2020-07-03 2025-11-12 CSL Innovation Pty Ltd HIGH-CONCENTRATION FORMULATION OF FACTOR XII ANTIGEN-BINDING PROTEINS

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240352150A2 (en) * 2020-06-16 2024-10-24 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
EP4729546A1 (en) * 2023-06-16 2026-04-22 Jiangsu BioJeTay Biotechnology Co., Ltd. Antibody specifically recognizing factor xiia and use thereof
IL325613A (en) * 2023-07-19 2026-02-01 Regeneron Pharma Antibodies against factor xii/xiia and their uses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
CA2082643A1 (en) 1990-05-10 1991-11-11 Jan H. Nuijens Inhibitors of factor xii activation and applications thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6891394B1 (en) * 2002-06-04 2005-05-10 Actel Corporation Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers
US7378867B1 (en) * 2002-06-04 2008-05-27 Actel Corporation Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CA2591786C (en) 2004-12-23 2013-07-16 Bernhard Nieswandt Prevention of thrombus formation and/or stabilization
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US7541838B2 (en) * 2007-03-27 2009-06-02 Intel Corporation Transmitter swing control circuit and method
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
EP2384766A1 (en) * 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel antibody to a carbonic anhydrase
CN103415301A (zh) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
ES3005912T3 (en) * 2011-07-22 2025-03-17 Csl Behring Gmbh Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR101461652B1 (ko) * 2011-12-16 2014-11-21 주식회사 삼양바이오팜 유착방지용 조성물, 이를 포함하는 유착방지기능을 갖는 수술용 메쉬 복합체 및 이의 제조 방법
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
TWI613215B (zh) * 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
WO2014089493A1 (en) * 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
KR20150139089A (ko) * 2014-06-02 2015-12-11 한국전자통신연구원 멀티플라이어 및 다중 입력 증폭기를 포함하는 전류-전압 변환 증폭 회로
US10259874B2 (en) * 2014-10-27 2019-04-16 Agency For Science, Technology And Research Anti-TIM-3 antibodies
CN111919424A (zh) * 2018-07-02 2020-11-10 拉姆伯斯公司 利用早期高阶符号检测用于判决反馈均衡的方法和电路

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4175669A4 (en) * 2020-07-03 2025-11-12 CSL Innovation Pty Ltd HIGH-CONCENTRATION FORMULATION OF FACTOR XII ANTIGEN-BINDING PROTEINS

Also Published As

Publication number Publication date
US12068729B2 (en) 2024-08-20
JP2024116399A (ja) 2024-08-27
JP2021527424A (ja) 2021-10-14
EP3810270A1 (en) 2021-04-28
KR20210022650A (ko) 2021-03-03
MX2020013894A (es) 2021-05-27
AU2019288299B2 (en) 2026-02-05
CN112437682A (zh) 2021-03-02
JP7634993B2 (ja) 2025-02-25
EA202190056A1 (ru) 2021-05-28
WO2019246176A8 (en) 2020-10-08
WO2019246176A1 (en) 2019-12-26
MA52966A (fr) 2021-04-28
IL279529A (en) 2021-01-31
US20210203292A1 (en) 2021-07-01
CN112437682B (zh) 2024-11-05
AU2019288299A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
US20230174631A1 (en) Anti-c5 antibodies and uses thereof
CA2904644C (en) Human antibodies to grem1
JP2024116399A (ja) 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
IL325613A (en) Antibodies against factor xii/xiia and their uses
US20240190996A1 (en) Factor xi catalytic domain-binding antibodies and methods of use thereof
US12304969B2 (en) Factor XI A2 domain-binding antibodies and methods of use thereof
EA048528B1 (ru) АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
JP7807238B2 (ja) 骨形成タンパク質６に対するヒト抗体
EA052707B1 (ru) Антитела, связывающие домен a2 фактора xi, и способы их использования
HK40110954A (en) Anti-c5 antibodies and uses thereof
EA041355B1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА К ТОКСИНУ ГЕМОЛИЗИНУ А S.aureus
HK40001079A (en) Anti-c5 antibodies and uses thereof
HK40001079B (en) Anti-c5 antibodies and uses thereof

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240821

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240821

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241016

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241016

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241016

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241016

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250526

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250526

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251112

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260310

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260312

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260312